{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:13:52Z","timestamp":1792826032025,"version":"4.5.0"},"reference-count":94,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Friedman Brain Institute, Icahn School of Medicine at Mount Sinai"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome that increases one\u2019s risk for both benign and malignant tumors. NF1 affects every organ in the body, but the most distinctive symptoms that are often the most bothersome to patients are the cutaneous manifestations, which can be unsightly, cause pain or pruritus, and have limited therapeutic options. In an effort to increase awareness of lesser-known dermatologic associations and to promote multidisciplinary care, we conducted a narrative review to shed light on dermatologic associations of NF1 as well as emerging treatment options. Topics covered include cutaneous neurofibromas, plexiform neurofibromas, diffuse neurofibromas, distinct nodular lesions, malignant peripheral nerve sheath tumors, glomus tumors, juvenile xanthogranulomas, skin cancer, and cutaneous T-cell lymphoma.<\/jats:p>","DOI":"10.3390\/cancers15102770","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:27:04Z","timestamp":1684204024000},"page":"2770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments"],"prefix":"10.3390","volume":"15","author":[{"given":"Dina","family":"Poplausky","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade N.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2480-0482","authenticated-orcid":false,"given":"Hansen","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Rivera-Oyola","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-4138","authenticated-orcid":false,"given":"Rebecca M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis","volume":"5","author":"Kresak","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.18632\/oncotarget.2194","article-title":"The NF1 gene revisited\u2014From bench to bedside","volume":"5","author":"Yap","year":"2014","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaad.2020.07.105","article-title":"Neurofibromatosis type 1: New developments in genetics and treatment","volume":"84","author":"Wilson","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.cdd.4402057","article-title":"The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways","volume":"14","author":"Shapira","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1600-0625.2009.01017.x","article-title":"Decreased expression of neurofibromin contributes to epithelial\u2013mesenchymal transition in neurofibromatosis type 1","volume":"19","author":"Arima","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"ref_7","unstructured":"Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (2023, February 08). Neurofibromatosis 1, GeneReviews\u00ae, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","article-title":"Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors","volume":"138","author":"Wang","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/cch.12496","article-title":"Psychosocial functioning, self-image, and quality of life in children and adolescents with neurofibromatosis type 1","volume":"44","author":"Cipolletta","year":"2018","journal-title":"Child Care Health Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"883019","DOI":"10.3389\/fpsyg.2022.883019","article-title":"Sexual Self-Esteem and Psychological Burden of Adults With Neurofibromatosis Type 1","volume":"13","author":"Leidger","year":"2022","journal-title":"Front. Psychol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2340\/00015555-2241","article-title":"Clinical Characteristics of Pruritus in Neurofibromatosis 1","volume":"96","author":"Brenaut","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R","article-title":"Neurofibromatosis type 1 and pregnancy","volume":"66","author":"Dugoff","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_14","first-page":"752","article-title":"Progesterone receptor expression in neurofibromas","volume":"63","author":"McLaughlin","year":"2003","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lammert, M., Mautner, V.F., and Kluwe, L. (2005). Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC Cancer, 5.","DOI":"10.1186\/1471-2407-5-16"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Well, L., Jaeger, A., Kehrer-Sawatzki, H., Farschtschi, S., Avanesov, M., Sauer, M., De Sousa, M.T., Bannas, P., Derlin, T., and Adam, G. (2020). The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232031"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","article-title":"Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial","volume":"18","author":"Slopis","year":"2018","journal-title":"Drugs RD"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13262","DOI":"10.1111\/dth.13262","article-title":"Successful treatment of cutaneous (dermal) neurofibromas with imatinib mesylate","volume":"33","author":"Chhabra","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1542\/peds.2013-1224","article-title":"Sirolimus Improves Pain in NF1 Patients with Severe Plexiform Neurofibromas","volume":"133","author":"Hua","year":"2014","journal-title":"Pediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA Approval Summary: Selumetinib for Plexiform Neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10503","DOI":"10.1200\/JCO.2018.36.15_suppl.10503","article-title":"SPRINT: Phase II study of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"36","author":"Gross","year":"2018","journal-title":"JCO"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1\u2013Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"National Cancer Institute (NCI) (2023, March 23). Pilot Study of the MEK1\/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02839720."},{"key":"ref_24","unstructured":"(2023, February 20). PhD SRP MD. Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults with Neurofibromatosis 1, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00865644."},{"key":"ref_25","first-page":"i107","article-title":"Management of cutaneous neurofibroma: Current therapy and future directions","volume":"2","author":"Chamseddin","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_26","unstructured":"NFlection Therapeutics, Inc (2023, April 13). A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects with Cutaneous Neurofibromas, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435665."},{"key":"ref_27","unstructured":"NFlection Therapeutics, Inc (2023, April 13). A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05005845."},{"key":"ref_28","unstructured":"Gulati, N. (2023, February 07). A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Treat Cutaneous Neurofibromas Associated with NF1, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05438290."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e128881","DOI":"10.1172\/jci.insight.128881","article-title":"Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1","volume":"4","author":"Chamseddin","year":"2019","journal-title":"JCI Insight"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bjps.2016.03.024","article-title":"The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment","volume":"69","author":"Lutterodt","year":"2016","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-4725.1987.tb00517.x","article-title":"CO2 laser treatment of cutaneous neurofibromas","volume":"13","author":"Roenigk","year":"1987","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00000637-199106000-00016","article-title":"Use of the Carbon Dioxide Laser in Treating Multiple Cutaneous Neurofibromas","volume":"26","author":"Becker","year":"1991","journal-title":"Ann. Plast. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13555-012-0007-5","article-title":"Carbon Dioxide Laser Treatment of Cutaneous Neurofibromas","volume":"2","author":"Chiang","year":"2012","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/00006534-199809020-00054","article-title":"Thermal injuries as a result of CO2 laser resurfacing","volume":"102","author":"Grossman","year":"1998","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1046\/j.1365-2133.2001.04214.x","article-title":"Carbon dioxide laser for removal of multiple cutaneous neurofibromas","volume":"144","author":"Moreno","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10103-013-1469-0","article-title":"Comparative study of CO2\u2212 and Er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen\u2019s disease","volume":"29","author":"Kriechbaumer","year":"2014","journal-title":"Lasers Med. Sci."},{"key":"ref_37","unstructured":"Yumeen, S., Hohman, M.H., and Khan, T. (2023, February 21). Laser Erbium-Yag Resurfacing, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560931\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1524-4725.2012.02357.x","article-title":"Successful Treatment of Multiple Cutaneous Neurofibromas Using a Combination of Shave Excision and Laser Photothermocoagulation with a 1,444-nm Neodymium-Doped Yttrium Aluminum Garnet Laser","volume":"38","author":"Kim","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_39","unstructured":"Anderson, R.R. (2023, March 23). Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04730583."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/photob.2020.4957","article-title":"Photodynamic Therapy for Benign Cutaneous Neurofibromas Using Aminolevulinic Acid Topical Application and 633\u2009nm Red Light Illumination","volume":"39","author":"Quirk","year":"2021","journal-title":"Photobiomodul. Photomed. Laser Surg."},{"key":"ref_41","unstructured":"Verma, N., Yumeen, S., and Raggio, B.S. (2023, February 24). Ablative Laser Resurfacing, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557474\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10103-007-0485-3","article-title":"Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation","volume":"23","author":"Elwakil","year":"2008","journal-title":"Lasers Med. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The Use of MEK Inhibitors in Neurofibromatosis Type 1\u2013Associated Tumors and Management of Toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mohamad, T., Plante, C., and Brosseau, J.P. (2021). Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168620"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: Current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The Diagnosis and Management of Neurofibromatosis Type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/PAS.0000000000000447","article-title":"Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: Clinicopathologic characterization in a series of 9 cases","volume":"39","author":"Schaefer","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"Akshintala","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","article-title":"Methylation-based classification of benign and malignant peripheral nerve sheath tumors","volume":"131","author":"Koelsche","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","article-title":"Malignant Peripheral Nerve Sheath Tumor: Models, Biology, and Translation","volume":"41","author":"Somatilaka","year":"2022","journal-title":"Oncogene"},{"key":"ref_51","first-page":"i50","article-title":"Genetics of human malignant peripheral nerve sheath tumors","volume":"2","author":"Pemov","year":"2019","journal-title":"Neurooncol. Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14992","DOI":"10.1038\/s41598-017-15183-1","article-title":"The genomic landscape of malignant peripheral nerve sheath tumors: Diverse drivers of Ras pathway activation","volume":"7","author":"Brohl","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ozarslan, B., Russo, T., Argenziano, G., Santoro, C., and Piccolo, V. (2021). Cutaneous Findings in Neurofibromatosis Type 1. Cancers, 13.","DOI":"10.3390\/cancers13030463"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.jaad.2020.08.129","article-title":"Subungual glomus tumors: Underrecognized clinical findings in neurofibromatosis 1","volume":"84","author":"Lipner","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/jmg.2009.073965","article-title":"Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1","volume":"47","author":"Stewart","year":"2010","journal-title":"J. Med. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.aott.2019.04.014","article-title":"An exceptional case of malignant glomus tumor and a review of the literature","volume":"53","author":"Sacchetti","year":"2019","journal-title":"Acta Orthop. Traumatol. Turc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1066896914567330","article-title":"Clinical and Histopathological Diagnosis of Glomus Tumor: An Institutional Experience of 138 Cases","volume":"23","author":"Mravic","year":"2015","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13256-018-1847-0","article-title":"Painful tumors in a patient with neurofibromatosis type 1: A case report","volume":"12","author":"Aqil","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_61","first-page":"63","article-title":"Glomus Tumor of the Thenar Eminence in Neurofibromatosis Type 1: Case Report and Literature Review","volume":"11","author":"Scaravilli","year":"2014","journal-title":"Transl. Med. UniSa."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaad.2014.01.913","article-title":"Glomus tumors in individuals with neurofibromatosis type 1","volume":"71","author":"Kumar","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jhsa.2013.05.025","article-title":"The association between glomus tumors and neurofibromatosis","volume":"38","author":"Harrison","year":"2013","journal-title":"J. Hand Surg. Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1097\/GOX.0000000000000144","article-title":"Glomus tumors and neurofibromatosis: A newly recognized association","volume":"2","author":"Harrison","year":"2014","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1158\/0008-5472.CAN-09-1752","article-title":"Glomus tumors in neurofibromatosis type 1: Genetic, functional and clinical evidence of a novel association","volume":"69","author":"Brems","year":"2009","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1161\/CIRCULATIONAHA.107.707752","article-title":"NF1 Regulates a Ras-Dependent Vascular Smooth Muscle Proliferative Injury Response","volume":"116","author":"Xu","year":"2007","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-020-00142-8","article-title":"Glomus tumors with malignant features of the extremities: A case series","volume":"10","author":"Wood","year":"2020","journal-title":"Clin. Sarcoma Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sanagoo, A., Jouybari, L., Koohi, F., and Sayehmiri, F. (2019). Evaluation of QoL in neurofibromatosis patients: A systematic review and meta-analysis study. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1338-y"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2013.6434","article-title":"Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1","volume":"150","author":"Ferrari","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_70","unstructured":"Collie, J.S., Harper, C.D., and Fillman, E.P. (2023, February 08). Juvenile Xanthogranuloma, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526103\/."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jaad.2016.12.012","article-title":"The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study","volume":"76","author":"Mohammed","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"40683","DOI":"10.18632\/oncotarget.16542","article-title":"Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations","volume":"8","author":"Cosgarea","year":"2017","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdin.2020.07.004","article-title":"The tumor genetics of acral melanoma: What should a dermatologist know?","volume":"1","author":"Tod","year":"2020","journal-title":"JAAD Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamadermatol.2022.3083","article-title":"Neurofibromatosis Type 1 and Risk of Skin Cancer","volume":"158","author":"Trinh","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/bjc.2012.535","article-title":"Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: Population-based record-linkage study","volume":"108","author":"Seminog","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of Cancer Prevalence in Patients with Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_79","first-page":"e371","article-title":"Cutaneous manifestations in neurofibromatosis type 1","volume":"171","author":"Miraglia","year":"2020","journal-title":"Clin Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00008390-200404000-00014","article-title":"Cutaneous malignant melanoma and neurofibromatosis type 1","volume":"14","author":"Guillot","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_82","first-page":"454","article-title":"An Update on Neurofibromatosis Type 1: Not Just Cafe-au-Lait Spots, Freckling, and Neurofibromas. An Update. Part I. Dermatological Clinical Criteria Diagnostic of the Disease","volume":"107","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_83","first-page":"465","article-title":"An Update on Neurofibromatosis Type 1: Not Just Cafe-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer","volume":"107","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jaad.2011.05.030","article-title":"Melanoma survival in the United States, 1992 to 2005","volume":"65","author":"Pollack","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ijwd.2021.05.005","article-title":"Skin cancer discovery during total body skin examinations","volume":"7","author":"Jiang","year":"2021","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/DAD.0000000000000697","article-title":"Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature","volume":"39","author":"Shamsuyarova","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1365-4362.2002.14472.x","article-title":"Neurofibromatosis type 1 and mycosis fungoides","volume":"41","author":"Braam","year":"2002","journal-title":"Int. J. Dermatol."},{"key":"ref_89","first-page":"27","article-title":"Cutaneous T-cell lymphoma in a patient with neurofibromatosis type 1","volume":"72","author":"Herbert","year":"2003","journal-title":"Cutis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00403-005-0564-x","article-title":"NF1 tumor suppressor in epidermal wound healing with special focus on wound healing in patients with type 1 neurofibromatosis","volume":"296","author":"Koivunen","year":"2005","journal-title":"Arch. Dermatol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/scs.0b013e31811f3587","article-title":"Multicenter study of wound healing in neurofibromatosis and neurofibroma","volume":"18","author":"Miyawaki","year":"2007","journal-title":"J. Craniofac. Surg."},{"key":"ref_93","unstructured":"McGinty, S., and Siddiqui, W.J. (2023, February 24). Keloid, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507899\/."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00006534-196912000-00006","article-title":"Keloids in various races. A review of 175 cases","volume":"44","author":"Alhady","year":"1969","journal-title":"Plast. Reconstr. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:44Z","timestamp":1760124944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":94,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102770"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102770","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}